The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

• 主要な著者: Hongmei Cui (著者), Qinghui Wang (著者), Duane D. Miller (著者), Wei Li (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15-20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma....